Related Experiment Video

Updated: May 16, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Vandetanib and the management of advanced medullary thyroid cancer

Michael J Campbell1, Carolyn D Seib, Jessica Gosnell

  • 1Department of Endocrine Surgery, University of California, San Francisco, San Francisco, California, USA.

Current Opinion in Oncology
|December 4, 2012
PubMed
Abstract

Insights

Vandetanib, a novel tyrosine kinase inhibitor, shows promise for treating advanced medullary thyroid cancer (MTC). It improves progression-free survival with manageable side effects, though QTc prolongation requires monitoring.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Medullary thyroid cancer (MTC) is a neuroendocrine malignancy often linked to RET proto-oncogene mutations.
  • Targeted therapies are crucial for managing advanced or metastatic MTC.
  • Small molecule tyrosine kinase inhibitors offer a new therapeutic avenue for MTC.

Purpose of the Study:

  • To review the efficacy and safety of vandetanib for medullary thyroid cancer.
  • To highlight vandetanib's mechanism of action in MTC treatment.
  • To discuss the clinical implications of vandetanib in MTC management.

Main Methods:

  • Review of clinical trial data and scientific literature on vandetanib in MTC.
  • Analysis of vandetanib's targeted pathways: RET, VEGFR-2, and EGFR.
  • Evaluation of progression-free survival and adverse event profiles.

Main Results:

  • Vandetanib improves progression-free survival in patients with advanced MTC.
  • The drug targets key signaling pathways (RET, VEGFR-2, EGFR) implicated in MTC.
  • Vandetanib is generally well-tolerated, with QTc prolongation as a notable side effect requiring monitoring.

Conclusions:

  • Vandetanib is an effective treatment option for advanced MTC, offering durable disease stabilization.
  • Its acceptable adverse event profile makes it a promising therapy.
  • Careful patient selection and monitoring are essential due to potential QTc prolongation.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...